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Methyl-binding domain (MBD) enrichment followed by deep sequencing (MBD-seq), is a
robust and cost efficient approach for methylome-wide association studies (MWAS). MBDseq has been demonstrated to be capable of identifying differentially methylated regions,
detecting previously reported robust associations and producing findings that replicate with
other technologies such as targeted pyrosequencing of bisulfite converted DNA. There are
several kits commercially available that can be used for MBD enrichment. Our previous
work has involved MethylMiner (Life Technologies, Foster City, CA, USA) that we chose
after careful investigation of its properties. However, in a recent evaluation of five commercially available MBD-enrichment kits the performance of the MethylMiner was deemed
poor. Given our positive experience with MethylMiner, we were surprised by this report. In
an attempt to reproduce these findings we here have performed a direct comparison of
MethylMiner with MethylCap (Diagenode Inc, Denville, NJ, USA), the best performing kit in
that study. We find that both MethylMiner and MethylCap are two well performing MBDenrichment kits. However, MethylMiner shows somewhat better enrichment efficiency and
lower levels of background “noise”. In addition, for the purpose of MWAS where we want to
investigate the majority of CpGs, we find MethylMiner to be superior as it allows tailoring the
enrichment to the regions where most CpGs are located. Using targeted bisulfite sequencing we confirmed that sites where methylation was detected by either MethylMiner or by
MethylCap indeed were methylated.

Introduction
The methylation of DNA cytosine residues at the carbon-5 position is a common epigenetic
modification. In mammalian somatic tissues this modification is most often, although not
exclusively, found in the context of CpG sequence. Methylation at critical sites can suppress
transcription [1] but more recent studies have also associated methylation with increased
expression levels [2]. Investigations of DNA methylation marks provide a promising
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complement to genetics studies of sequence variation as it can, for example, link genetic and
environmental effects.
The most comprehensive approach to study genome-wide DNA methylation is whole
genome bisulfite sequencing (WGBS), where unmethylated cytosines are converted to uracil
[3] and the methylation status of each site is determined after deep sequencing. However, due
to the combination of high costs of sequencing entire genomes and the large numbers of samples required for adequate statistical power, this approach is currently not economically feasible
for methylome-wide association studies (MWAS) [4].
We have found that methyl-binding domain (MBD) enrichment followed by sequencing
(MBD-seq), is a robust and cost efficient approach for MWAS [5]. With this approach, we first
fragment the DNA and then aim to extract only the methylated fragments using a protein with
high affinity for methylated CpGs [6]. This is more cost-effective than WGBS as only the methylation-enriched DNA portion is used for sequencing [6–8]. MBD-seq has already been demonstrated to be sensitive and capable of identifying differentially methylated regions [6, 8–11],
detecting previously reported robust associations [12] and producing findings that replicate
when using “gold standard” technologies such as targeted pyrosequencing of bisulfite converted DNA [13].
There are several kits commercially available that can be used for MBD enrichment. Our
previous work has involved MethylMiner (Life Technologies, Foster City, CA, USA) [5, 13].
Prior to using this kit, we carefully investigated its properties. These evaluations suggested
that the background noise level of MethylMiner is relatively low, (the ratio between the median
coverage for a CpG, i.e., the methylation signal, versus a non-CpG, i.e., the background noise,
was 40.6) and that a good enrichment of methylated fragments can be obtained [5]. Another
appealing feature is that methylome-wide coverage can be optimized by using a protocol version where the enriched fraction is eluted with a low salt concentration [5].
Given our positive experience with MethylMiner, we were surprised to learn that in a recent
evaluation of five commercially available MBD-enrichment kits [14] the performance of the
MethylMiner was deemed poor. In an attempt to reproduce these findings we here have performed a direct comparison of MethylMiner with MethylCap (Diagenode Inc, Denville, NJ,
USA), which in the previous evaluation was considered the most optimal MBD enrichment kit
[14].
Both MethylMiner and MethylCap use proteins for enrichment of the CpG methylated fraction of the genome. MethylMiner uses a biotin conjugated methyl-CpG binding domain
(MBD) of human Methyl-CpG-binding domain protein 2 (MBD2). The biotin epitope of the
MethylMiner protein allows for pulldown of captured DNA with paramagnetic streptavidin
beads. Exploiting the sensitivity of protein-DNA interactions to increasing salt concentrations,
MethylMiner allows the user to elute DNA fractions based on the density of methylated CpGs.
Instead of MBD2 MethylCap uses a fusion protein of the MBD of human methyl-CpG-binding
protein 2 (MECP2) and Glutathione-S-transferase (GST). The GST domain of the MethylCap
fusion protein binds then to glutathione coated paramagnetic beads for extraction.
To compare the two kits we performed methylome wide profiling for each kit using the
same two mice, in duplicates. To further evaluate our findings, a number of randomly selected
CpGs from sites where we observed differences were validated in the same samples, in duplicate, using targeted bisulfite pyrosequencing. Furthermore, to evaluate whether the methylome-wide coverage of MethylCap could target regions with different CpG densities a third
mouse was investigated with MethylCap using the lowest and the highest elution buffer concentrations recommended. This data was compared with previously unpublished data from a
similar evaluation of MethylMiner conducted in two human samples.
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Materials and Methods
Preparation of DNA
Adult DBA2/J male mice from Jackson Laboratories (Bar Harbor, ME, United States) were
housed 4 per cage on a 12-h/12-h light/dark cycle in an AAALAC-accredited animal facility
with continuous access to standard chow (Harlan Teklad #7912, Madison WI) and water. At
the time of tissue extraction cervical dislocation was performed and striatum brain tissue was
extracted from each mouse. Tissue was frozen in liquid nitrogen and stored in -80°C until
DNA extraction. All procedures for housing and handling the animals were approved by the
Virginia Commonwealth University Institutional Animal Care and Use Committee under protocol number AM10332 and carried out in strict accordance with the recommendations in the
National Institute of Health Guide for the Care and Use of Laboratory Animals (NIH Publications No. 80–23, 1996).
Genomic DNA was extracted from brain tissue using the Gentra Puregene Blood/Tissue Kit
(Qiagen, Valencia, CA) following the vendor’s instructions. The DNA was fragmented into a
median length of 180 base pairs using ultrasonication with the Covaris S2 instrument (Covaris,
Woburn, MA, USA). The fragmentation was performed in frequency sweeping mode for 6
cycles using the following conditions: duty cycle 10%, intensity 5, and 100 cycles per burst during 60 seconds. The water temperature limit was set to 15°C and the water temperature was
maintained at 5°C. For each mouse, DNA was fragmented in amounts of 3 μg and pooled prior
to further procedures. Thus, the fragment length distribution was identical for all conditions
investigated from the same mouse. The length of the fragmented DNA was determined with
the Agilent High Sensitivity Kit on an Agilent Bioanalyzer 2100 (Agilent Technologies, Santa
Clara, CA, USA) and the DNA was quantified with the NanoDrop ND-1000 spectrophotometer (Thermo Fisher Scientific, Wilmington, DE).

Methylation enrichment
The amount of starting material for each methylation enrichment reaction was 1.5 μg of DNA
for both MethylMiner and MethylCap. The standard MethylCap protocol specifies using up to
1.0 μg of genomic DNA as starting material. Therefore, we followed advice from the vendor
and adjusted the reagent volumes accordingly to accommodate for the 1.5 μg used in this
study. Except for the minor adjustment made to obtain comparable amounts of input material,
enrichment for both kits was performed according to standard protocols with the lowest salt
concentration recommended for elution (0.5M NaCl and Low Elution Buffer– 0.5M, for
MethylMiner and MethylCap, respectively). As summarized in Table 1, the two capture methods were performed for the same two samples. To study the reproducibility of these assays we
also used technical duplicates. To study the effects of altered salt concentrations for elution we
also performed enrichments with MethylCap in a third mouse. For these enrichments we used
the lowest (Low Elution Buffer– 0.5M) and the highest (High Elution Buffer—0.8M) salt concentrations recommended for MethylCap.

Library preparation and sequencing
The methylation-enriched DNA from MethylMiner (mean = 296.5 ng, SD = 21.4) and MethylCap (mean = 95.8 ng, SD = 17.7), respectively, was used as input materials for barcoded fragment libraries for SOLiD5500xl Wildfire deep sequencing. This library construction protocol
allows for 10 ng to 5 μg of DNA to be used as starting material. The protocol includes size selection of fragments of optimal length for the sequencing. This size selection prevents any unexpected long or short fragments from being included in the sequencing. Each library was
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Table 1. Overview of study design for the MethylMiner versus MethylCap comparison and number of reads in each condition. Captured DNA (ng)
indicates the amount of DNA that was captured in the MBD enrichment; % Mapped Reads are percent of the Total Reads that successfully aligned and %
Used Reads are percent of the Total Reads that successfully aligned and remained after rigorous quality control.
Individual

Technical Duplicate

MBD-capture Kit

Captured DNA (ng)

Total Reads

% Mapped Reads

% Used Reads

A

1

MethylMiner

284

32,786,373

71.9

28.2

A

2

MethylMiner

273

43,543,509

71.9

25.1

A

1

MethylCap

77

32,213,938

72.9

29.9

A

2

MethylCap

85

23,883,650

74.0

30.3

B

1

MethylMiner

317

48,397,266

72.2

32.2

B

2

MethylMiner

312

42,712,240

70.5

34.0

B

1

MethylCap

115

31,148,759

74.0

34.9

B

2

MethylCap

106

29,959,582

72.9

31.5

doi:10.1371/journal.pone.0132205.t001

sequenced using single-end chemistry at 50 bp read length. After deleting reads with more
than 2 missing color calls, for the eight samples in the primary comparison, we obtained on
average 35.6 million reads per sample (SD = 8.3 million).

Alignment, quality control, and coverage calculations
The sequenced reads were aligned to the DBA2/J (D2) specific reference genome[15] (see supplementary materials for details about the reference genome, S1 Text) using BioScope 1.2 (Life
Technologies). The mean percentage of mapped reads was 71.6% (SD = 0.8) for MethylMiner
and 73.5% (SD = 0.6) for MethylCap. We have previously developed an analysis pipeline for
MBD-seq that includes rigorous quality control for methylome-wide investigations[5]. This
quality control includes exclusion of duplicate reads (i.e. reads starting at the same location)
likely to be caused by amplification artifacts, and exclusion of low-quality multi reads (i.e.
reads that align equally well to a large number of locations in the genome). After exclusion of
low quality multi reads and duplicate reads 39.6% (sd = 3.5) and 45.1% (sd = 1.8) of the
mapped reads were retained for MethylMiner and MethylCap, respectively. It should be noted
that the percentage of reads remaining after quality control (i.e. used reads) are slightly lower
than what we typically see when working with more established reference genomes such as the
human genome and the commonly used C57BL6 mouse genome.
The MBD proteins have high affinity to methylated CpGs but not to methylated Cs (CpH)
outside the context of CpGs. Therefore, we considered only the 20.3 million CpG sites in the
autosomal mouse reference genome for our analysis. Methylation measurements were obtained
by estimating how many fragments covered each CpG, which gives a more precise measurement than, for example, counting the reads or extended reads (e.g. to the expected fragment
length) covering each CpG[16]. The method is described elsewhere in detail[16]. In summary,
using the distribution of reads around isolated CpGs, we first obtained non-parametric estimates of the fragment size distribution for each sample. The sample-specific estimated fragment size distribution was then used to calculate the probability for each read that the
fragment it is tagging covers the CpG under consideration. Coverage estimates for each CpG
were then calculated for each subject by taking the sum of the probabilities that all fragments in
its neighborhood cover the CpG. Coverage estimates obtained with this method show very
high correlations (R = 0.999) with estimates obtained using paired-end libraries where fragment size distributions are known[16]. The coverage calculations are standardized on the total
number of used reads for each sample.
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Enrichment efficiency
Reads aligned to regions that lack CpGs will yield an estimate of the non-specific binding (i.e.
“noise”), which can be used to estimate the enrichment efficiency of each kit. Here we used the
95th percentile of the coverage estimates at non-CpGs (defined here as sites located at least 400
bp from any known CpG) as the threshold for “noise”. Thus, sites with a coverage estimate that
exceeds the threshold for noise are considered methylated.

Percent of CpG coverage
For optimal methylome-wide coverage it is important that the sequenced fragments cover the
vast majority of CpGs. To study this, we first calculated the local CpG density (also called coupling factor[17]) by counting the number of CpGs within 100 bp on either side of a target CpG.
Next, we calculated a percent of CpG coverage measure denoted as Cds , that roughly speaking
can be interpreted as the portion of all fragments covering sites with a local CpG density of d;
as follows:
0
N ðC  C95
Þ
Cds ¼ Pk d d
0
d¼1 Nd ðCd  C95 Þ

ð1Þ

Thus, Cds is the standardized version of Cd, with Nd being the number of sites in the genome
that have local CpG density d, Cd = Mean(C|D = d) or the (conditional) mean coverage C of
0
is the threshold for background noise for the tested kit estisites with local CpG density d, C95
th
mated using the 95 percentile of non-CpG coverage, and k the maximum CpG density.

Validation with targeted bisulfite pyrosequencing
Differences between MethylMiner and MethylCap were further studied with an independent
technology. This validation was performed using aliquots of the same DNA samples as were
used for the MBD-seq analysis. Genomic DNA was bisulfite converted using Epitect 96
(QIAGEN, Germantown, MD). For each assay, the bisulfite converted DNA was used as input
material for the PyroMark PCR in a total reaction volume of 12.5 μl. In the PyroMark pyrosequencing reactions (QIAGEN, Germantown, MD) 2.5 μl of the amplicons were used. With the
exception that we used universal primers[18, 19], all procedures were conducted according to
the standard protocols provided by the vendor. Each pyrosequencing assay was designed using
the PyroMark Assay Design software (QIAGEN, Germantown, MD). All DNA samples were
investigated in duplicates.
In addition to the investigated samples, each assay included analysis of four different negative controls and three standards with known methylation levels. The negative pyrosequencing
controls consisted of 1) PCR product conducted without DNA, replaced with H2O, 2) pyrosequencing reaction without amplicon and PCR primers, 3) pyrosequencing reaction without
amplicon but with the biotinlylated PCR primer included, 4) pyrosequencing reaction without
the sequencing primer and without amplicon but with the biotinlylated PCR primer included.
The known standards included three DNA samples in duplicates with known methylation levels (0%, 50% and 100% methylation). The methylation standards were created using fully
methylated control DNA, following the recommended protocol for “Methylation of Genomic
DNA” (New England BioLab, Ipswich, MA) and unmethylated control DNA, using the
REPLI-g amplified DNA protocol (QIAGEN, Germantown, MD) created from the same
DBA2/J mouse strain.
All assays passed careful quality control. First, all negative controls were checked to be truly
negative. Next, the known standards were checked to have values in the approximate range of
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the expected methylation level. Similar to what we previously have seen in other studies, we
occasionally noticed that, although values were linear, the methylation levels for the known
standards were shifted for different CpG sites within the same assay or consistently slightly
shifted for an entire assay. These assays were still evaluated as good quality assays, as the shifts
are likely to be true observations, caused by slightly variable methylation levels in the synthetically created fully methylated and unmethylated DNA. In addition, the pyrograms of the
known standards and the DNA samples to be investigated were checked to match the reference
sequence pattern and the peak heights were checked to match the histogram of expected values.
Finally, to ensure that the bisulfite conversion was sufficient we included bisulfite conversion
controls in all assay where possible.

Results
Table 1shows the amount of DNA captured, the number of total reads, aligned reads, and
reads that remained after quality control. When comparing the estimated coverage for each
CpG site from our technical duplicates we observed a Pearson correlation of 0.838 and 0.851
for MethylMiner and 0.867 and 0.883 for MethylCap. These correlations indicate reproducibility, and suggest that the enrichment was successful for both kits. Furthermore, the relatively
high correlations between the technical duplicates suggest that the performance of the enrichment was not negatively affected by using a slightly increased amount of DNA as starting
material.
Fig 1shows the percentiles of the average estimated coverage for CpGs and non-CpGs,
respectively. Results show that the coverage for non-CpGs is generally lower for MethylMiner
than for MethylCap, whereas coverage for CpGs is generally higher for MethylMiner than for
MethylCap. Furthermore, for MethylMiner 59% of the CpGs show coverage estimates that are
higher than the threshold for background noise (i.e., can be considered methylated), whereas
for MethylCap the corresponding value is 42%. Thus, MethylMiner shows less noise and better
enrichment than MethylCap.

Fig 1. Methylation signals and levels of background noise. The mean coverage of CpGs and non-CpGs
from MethylMiner and MethylCap, respectively are shown. The horizontal lines indicate the threshold for
background noise as determined by the 95th percentile of the estimated coverage of the non-CpGs for
MethylMiner and MethylCap, respectively.
doi:10.1371/journal.pone.0132205.g001
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Fig 2. The overlap of MethylMiner and MethylCap with local CpG density. The local CpG density is
plotted against the percentage CpG coverage. The distribution of the local CpG density in the reference
sequence is the highest outside of CpG-rich regions. Better coverage of the regions where the majority of
CpGs occur (in the range of 1–7 CpGs) is obtained with MethylMiner than with MethylCap.
doi:10.1371/journal.pone.0132205.g002

In total, the MethylMiner kit detected 12,026,178 methylated sites and the MethylCap kit
detected 8,601,775 methylated sites. The overlap between the two kits was 7,888,063 sites. S1
Table gives the number of methylated sites uniquely detected by each of the two kits as well as
the number of sited detected by both kits for each CpG density.
In Fig 2the local CpG density is plotted against the percent CpG coverage measure Cds , for
MethylMiner and MethylCap, respectively. To evaluate if the percent of CpG coverage measures were signiﬁcantly different between MethylMiner and MethylCap we randomly selected
10,000 independent sites for each density (a maximum of 1 site was selected per 400bp to avoid
correlated observation that would violate assumptions underlying our statistical test) from
across the genome and compared their methylation status (methylated vs. unmethylated) using
a chi square test. Using a stringent threshold of α = 0.01 that was Bonferroni corrected for 20
tests (one for each CpG density) the threshold for declaring signiﬁcance was 5.00x10-04. For
each of the CpG densities from 1 to 11 our results indicate signiﬁcant differences between the
number of methylated CpGs detected with MethylMiner as compared to MethylCap (p ranging
from 9.66x10-07 to <5.98x10-283). In contrast, when studying each of the CpG densities
between 12 and 20 CpGs we did not observe signiﬁcant differences between the two kits.
Furthermore, our results show that the distribution of CpGs in the genome more closely
resembles the distribution of the standardized coverage as observed for MethylMiner than for
MethylCap. Because MethylMiner overlaps much better with the distribution of CpGs across
the genome, it provides better coverage and therefore a more complete investigation of the
CpG methylome across all CpG densities.

Validation of discrepancies using targeted bisulfite pyrosequencing
In the most optimal scenario we would validate all detected discrepancies using an independent
technology, such as e.g. whole genome bisulfite sequencing or similar techniques. In the
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absence of funding for such a comprehensive validation we have instead preformed a targeted
validation of selected sites. We designed pyrosequencing assays for ten randomly selected sites
in the CpG density range of 1–2, that were considered methylated by MethylMiner but were
methylation was not detected using MethylCap, and for three sites that were considered methylated by MethylCap but where methylation was not detected by MethylMiner. In addition, we
also designed pyrosequencing assays for ten randomly selected sites in the CpG density range
of 9–11, that were considered methylated using MethylCap but were methylation was not
detected using MethylMiner.
Due to challenges in the DNA sequences, in particular in regions with low sequence complexity due to high GC content, high quality assays could not be designed for all selected loci.
Therefore, after in silico evaluation eight, three and six assays were performed for the three
selection categories described above, respectively. The primers used for the assays and the coordinates for the investigated sites are given in S2 and S3 Tables.
When performing validation of sites detected as methylated by MethylMiner but not by
MethylCap, using targeted bisulfite pyrosequencing, we found that all sites had a high level of
methylation. The methylation levels for the two investigated samples for the eight investigated
sites ranged from 68.8% to 98.1% (see S4 Table for sample specific methylation levels for each
locus). Thus, for all investigated sites the validation results indicated that MethylMiner correctly detected the presence of methylation at these sites. Similarly, when performing validation
of sites with low CpG density detected as methylated by MethylCap but not by MethylMiner,
we also observed a relatively high level of methylation ranging from 52.8% to 95.7% (S5
Table). In contrast, for sites in high CpG density regions that were detected by MethylCap but
not by MethylMiner the methylation levels were relatively low, ranging from 10.9% to 32.6%
(S6 Table). Thus, the validation results indicated that also MethylCap correctly detected the
presence of methylation at these sites.

Targeting the CpG density of interest
According to the manufacturer the distribution of the methylated fraction enriched for by
MethylMiner can be shifted towards CpG richer regions by increasing the salt concentration of
the elution buffer (see the application note for MethylMiner [20]). To validate this claim we
previously performed an evaluation using human DNA that were part of our recent methylome-wide investigations[5]. Fig 3shows previously unpublished data from this comparison of
two human samples. The percentage CpG coverage measure Cds is plotted against the local CpG
density. Best coverage of the regions where the majority of CpGs are (i.e. the range of 1–7
CpGs) is obtained by a single MethylMiner elution using a low salt (0.5M NaCl) buffer. Using
a single elution with a higher salt (2.0M NaCl) concentration moves the percentage of CpG
coverage distribution in the direction of CpG dense regions. However, as relatively few CpGs
are located in dense regions, the overall coverage of the methylome is reduced with a high salt
elution. This effect is even further enhanced if a double elution is performed where the low salt
elution is discarded and only the second elution, performed with the higher salt concentration,
is sequenced. Thus, these results suggest that using a low salt concentration will give the most
comprehensive coverage of the CpG methylome that can be achieved with the MethylMiner
kit.
To evaluate if the methylome-wide coverage of MethylCap could target regions with different CpG densities we in this study performed a similar evaluation in a third mouse. For this
additional mouse sample MethylCap was performed using the lowest and the highest elution
buffer concentrations recommended by the vendor.

PLOS ONE | DOI:10.1371/journal.pone.0132205 July 15, 2015
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Fig 3. The effect of altered salt concentrations for elutions in MethylMiner. The shown data was generated as part of our recent methylome-wide
investigations in humans[5]. The local CpG density is plotted against the percentage CpG coverage for two randomly selected individuals in the upper and
lower graph, respectively. As expected, the unenriched genomic DNA closely follows the distribution of the CpG density in the reference genome. Best
coverage of the regions where the majority of CpGs occur (in the range of 1–7 CpGs) is obtained by a single MethylMiner elution using a low salt (0.5M NaCl)
buffer. Using a single elution with a higher salt (2.0M NaCl) concentration moves the distribution to regions with higher CpG density. If performing a double
elution where the low salt elution is discarded and only the 2nd fraction eluted with the high salt buffer is investigated, the distribution is shifted even further to
the right excluding regions with low local CpG density and focusing mainly in regions with high CpG density.
doi:10.1371/journal.pone.0132205.g003

Fig 4shows that when the concentration of the elution buffer was altered for MethylCap we
did not observe a notable shift of the percent CpG coverage. Therefore, under the conditions
used in this study, the elution conditions for MethylCap cannot be easily adapted to improve
enrichment for the CpG densities where the majority of CpGs are found.

PLOS ONE | DOI:10.1371/journal.pone.0132205 July 15, 2015
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Fig 4. The effect of altered salt concentrations for elutions in MethylCap. The local CpG density is
plotted against and the percentage CpG coverage. The distribution of the local CpG density in the reference
genome is shown. The distribution of CpG coverage for MethylCap is shown when using a low salt elution
buffer and when using a high salt elution buffer.
doi:10.1371/journal.pone.0132205.g004

Discussion
We found that MethylMiner and MethylCap both yield sufficient amounts of methylation
enriched DNA for construction of high quality sequencing libraries. The total number of reads,
percentage of mapped reads and the percentage of reads passing quality control were similar
for the two enrichment kits. We also found that the sample correlations of the estimated methylation coverage between technical duplicates (0.838 and 0.851 for MethylMiner; 0.867 and
0.883 for MethylCap were similar for the two kits. Although these correlations suggest some
noise, they also indicate a consistency in the enrichment procedure for both kits. Thus, the
MBD-seq protocols were successful for both kits and the results were comparable.
We also observed that with MethylMiner the coverage of CpGs was higher and background
“noise” lower. These results are in line with previous studies suggesting that the MBD2 protein,
which is used in MethylMiner, has a stronger affinity for methylated CpGs vs. unmethylated
DNA than what has been observed for the MeCP2 protein[21, 22]. The better detection of
CpGs from CpG poor regions and the better signal to noise ratio translate to being able to
detect more CpGs. Indeed, MethylMiner detected 59% and MethylCap 42% methylated CpGs.
The 59% methylated CpGs in mouse brain detected with MethylMiner is in line with what
recently has been reported. Using whole-genome bisulfite sequencing Lister et al. found ~60–
70% methylated CpGs in frontal cortex from mice of age 4 weeks to 22 months[23]. Although,
the most comprehensive comparison would include whole-genome bisulfite sequencing of the
same samples as were used in the present study, there are no indications that the percentage of
sites detected in our current investigation is limited by the specificity of MethylMiner but
rather that it reflects the methylome of the investigated mice or the methodological set up used,
which is not directly related to MethylMiner. For example, for all MBD-seq approaches the
specificity is a combination of the sensitivity of the kit and the number of used sequence reads.
Thus, if the enrichment kit has a high sensitivity but the number of used reads is low, the specificity may still be limited and regions where methylation is moderate may not be covered. The
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previous study in humans[5] included more than twice as many reads as we used in the present
study. This difference, which results in altered specificity, may partly contribute to the different
percentage of methylated CpGs observed in this study and in the previous human study.
Our evaluation of MethylMiner and MethylCap came to a dramatically different conclusion
compared to the previous evaluation of these kits, which reported that MethylMiner lacks sensitivity and specificity[14]. In contrast, we found that both MethylMiner and MethylCap were
two well performing MBD-enrichment kits, where MethylMiner performed better than
MethylCap in terms of enrichment efficiency and gave a better coverage of CpG poor regions
where most of the CpGs are located.
It should be noted that there are a number of differences between the present work and the
study previously published by De Meyer et al. For example, the previous work was exclusively
conducted in human cell lines while the present work is conducted in brain tissue from the
DBA2/J mouse strain and from human blood samples. However, given that the two DNA binding proteins used by MethylMiner and MethylCap both bind to the same type of DNA methylation (methylated CpG sites) discrepancies in performances between the two kits are unlikely
to be caused by the origin of the DNA. Other differences between the two studies included a
number of lab technical variables such as elution conditions of the captured methylated DNA
and the sequencing chemistry/platforms used. In addition to using MethylMiner in combination with sequencing on SOLiD platforms we have previously also successfully used MethylMiner with human DNA in combination with other sequencing platforms including both MiSeq
(Illumina) and NextSeq500 (Illumina) (unpublished data). Thus, while it is possible the differences in design and set up between our present study and the previous study by De Meyer et al.
may have some effects on the results it is unlikely that any, or all, of these factors would have
caused the MethylMiner enrichment to completely fail in the way that was reported by De
Meyer et al [14].
A more critical difference between the present and the previous study by De Meyer et al.
may be the amount of starting material used for the enrichment protocols and whether the
amount of DNA in the enriched fraction is sufficient for high quality library construction. We
have previously shown that the amount of starting material is of importance to sufficiently
extract the methylated fraction of the genome and subsequently create a complex sequencing
library [24]. We experienced that optimal quality MBD-seq analysis with MethylMiner and the
sequencing protocols described in the current work was achieved when starting with >500 ng
DNA as input material for MethylMiner. When using the standard MethylMiner protocol and
decreasing the amount of starting material to 250 ng we observed somewhat decreased performance[24] and when further decreasing the amount of starting material we repeatedly
observed a much lower signal to noise ratio (unpublished data). Although it is unlikely that the
procedure would completely fail by using slightly less than 250 ng starting material it should be
encouraged to use a modified protocol, provided by the vendor (Life Technologies, Foster City,
CA, USA), which is optimized for sub-micrograms of starting material.
The amount of starting material used for the methylation enrichment in the previous
evaluation by De Meyer et al. was 200 ng DNA and the amount enriched material used for the
subsequent library construction ranged from 1.75 ng to 48.30 ng. While there are library construction protocols that have been optimized to successfully handle low amounts of input
material, the previous evaluation[14] used a protocol that typically calls for 1–5 ug of DNA as
starting material. Thus, the poor performance of MethylMiner reported previously may not
reflect MBD-enrichment capacity, but may be caused by problems in the library construction
process.
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Conclusions
We find that both MethylMiner and MethylCap are two well performing MBD-enrichment
kits. However, MethylMiner show somewhat better enrichment efficiency and lower levels of
background “noise”. In addition, for the purpose of MWAS where we want to investigate the
majority of CpGs, we find MethylMiner to be superior as it allows tailoring the enrichment to
the regions where most CpGs are located.
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